Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OUVUO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CD79b-RKAA-MMAE ADC
|
|||||
| Synonyms |
Anti-CD79b-RKAA-MMAE ADC
Click to Show/Hide
|
|||||
| Organization |
Araris Biotech AG, Au ZH, Switzerland.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
B-cell antigen receptor complex-associated protein beta chain (CD79B)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
RKAA-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
RKAA-PABC-MMAE
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 10.3 | day |
The terminal ADC half-lives for anti-CD79-RKAA-MMAE and PV were 10.3 and 5.0 days, respectively.
|
[1] |
References